Galderma's Guidance Seems Conservative Amid Nemluvio's Success -- Market Talk

Dow Jones

Oct 06, 2025

0802 GMT - Galderma's sales target for this year looks conservative, given the success of its dermatitis drug Nemluvio, Vontobel analyst Stefan Schneider says in a research note. The analyst expects the Swiss skincare company to raise its sales guidance, assuming that sales of Nemluvio were 7% ahead of consensus during the third quarter. "Management has done a great job of positioning Nemluvio in the competitive pharma market," Schneider says. Furthermore, the analyst believes that L'Oreal and Galderma could expand their existing scientific partnership, which would make strong strategic sense. Vontobel upgrades its rating on Galderma to buy from hold. Shares trade 0.2% higher at 140.30 Swiss francs. (andrea.figueras@wsj.com)

(END) Dow Jones Newswires

October 06, 2025 04:02 ET (08:02 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2573288627"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573288627\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573288627?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 16:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573288627","market":"sh","top_or_hot":-1,"title":"Galderma's Guidance Seems Conservative Amid Nemluvio's Success -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0802 GMT - Galderma's sales target for this year looks conservative, given the success of its dermatitis drug Nemluvio, Vontobel analyst Stefan Schneider says in a research note. The analyst expects the Swiss skincare company to raise its sales guidance, assuming that sales of Nemluvio were 7% ahead of consensus during the third quarter. \"Management has done a great job of positioning Nemluvio in the competitive pharma market,\" Schneider says. Furthermore, the analyst believes that L'Oreal and Galderma could expand their existing scientific partnership, which would make strong strategic sense. Vontobel upgrades its rating on Galderma to buy from hold. Shares trade 0.2% higher at 140.30 Swiss francs. (andrea.figueras@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 06, 2025 04:02 ET (08:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Galderma's Guidance Seems Conservative Amid Nemluvio's Success -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGalderma's Guidance Seems Conservative Amid Nemluvio's Success -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-06 16:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0802 GMT - Galderma's sales target for this year looks conservative, given the success of its dermatitis drug Nemluvio, Vontobel analyst Stefan Schneider says in a research note. The analyst expects the Swiss skincare company to raise its sales guidance, assuming that sales of Nemluvio were 7% ahead of consensus during the third quarter. \"Management has done a great job of positioning Nemluvio in the competitive pharma market,\" Schneider says. Furthermore, the analyst believes that L'Oreal and Galderma could expand their existing scientific partnership, which would make strong strategic sense. Vontobel upgrades its rating on Galderma to buy from hold. Shares trade 0.2% higher at 140.30 Swiss francs. (andrea.figueras@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 06, 2025 04:02 ET (08:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LRLCY","symbol_name":"欧莱雅","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2573288627","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573288627","pubTimestamp":1759737720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0802 GMT - Galderma's sales target for this year looks conservative, given the success of its dermatitis drug Nemluvio, Vontobel analyst Stefan Schneider says in a research note. The analyst expects the Swiss skincare company to raise its sales guidance, assuming that sales of Nemluvio were 7% ahead of consensus during the third quarter. \"Management has done a great job of positioning Nemluvio in the competitive pharma market,\" Schneider says. Furthermore, the analyst believes that L'Oreal and Galderma could expand their existing scientific partnership, which would make strong strategic sense. Vontobel upgrades its rating on Galderma to buy from hold. Shares trade 0.2% higher at 140.30 Swiss francs. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LRLCY":"欧莱雅","BK4183":"个人用品"},"translate_title":"在Nemluvio的成功中，Galderma的指导似乎很保守——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LRLCY":0.9},"content_text":"0802 GMT - Galderma's sales target for this year looks conservative, given the success of its dermatitis drug Nemluvio, Vontobel analyst Stefan Schneider says in a research note. The analyst expects the Swiss skincare company to raise its sales guidance, assuming that sales of Nemluvio were 7% ahead of consensus during the third quarter. \"Management has done a great job of positioning Nemluvio in the competitive pharma market,\" Schneider says. Furthermore, the analyst believes that L'Oreal and Galderma could expand their existing scientific partnership, which would make strong strategic sense. Vontobel upgrades its rating on Galderma to buy from hold. Shares trade 0.2% higher at 140.30 Swiss francs. (andrea.figueras@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 06, 2025 04:02 ET (08:02 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}